Opioid Induced Constipation Drug Development 2018 – Pipeline Analysis Report – ResearchAndMarkets.com

The “2018
Opioid Induced Constipation (OIC) Drug Development- Pipeline Analysis
Report” report has been added to ResearchAndMarkets.com’s

With an estimated $600 million market value, the Opioid Induced
Constipation (OIC) is one of the most common gastrointestinal
conditions, presenting robust opportunities for development of treatment

To assist investigators and funding and regulatory organizations, the
publisher has come up with a comprehensive report on Opioid Induced
Constipation (OIC) pipeline. The report provides insights into different
therapeutic candidates in preclinical, research, discovery, NDA/IND, pre
registration, phase 1, phase 2, and phase 3 trials). Drugs under
development directly and through combination with other drugs are also

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Opioid Induced
Constipation (OIC) pipeline product. Mechanism of Action and the target
area of the pipeline product are also provided. Further, clinical and
preclinical trials along with results of the trials are also included in
the report.

In addition to complete details of each product, the report provides key
trends in Opioid Induced Constipation (OIC) pipeline studies. The
products under development are categorized according to their
development phase, mechanism and company to provide detailed insights
into the type of drugs being developed and the stages of development.

Key Topics Covered:

1 Opioid Induced Constipation Pipeline Analysis

2 Opioid Induced Constipation- Company Wise Pipeline Analysis

3 Opioid Induced Constipation R&D Pipeline Snapshots

4 Recent Developments in Opioid Induced Constipation Pipeline

5 Appendix

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/research/d7r9pl/opioid_induced?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005440/en/

Leave a Comment